Ensysce Biosciences, Inc. cotiza a 0.56 USD y tiene una capitalización bursátil de $11M. En los últimos 12 meses ha facturado $5M con un margen de flujo de caja libre del -156.5%. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, develops prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection (TAAP) platform, designed to release clinically effective drugs only when expos…
| Periodo | 2026-05 | 2026-03 | 2025-11 | 2025-08 |
|---|---|---|---|---|
| Real | $-0.52 | $-0.75 | $-1.29 | — |
| Estimado | $-0.73 | $-1.26 | $-0.93 | $-1.28 |
| Sorpresa | +28.8% | +40.5% | -38.7% | — |
| Métrica | ENSC | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | -202.1% | -38.6% | -163.5% |
| Net Margin | -200.8% | -33.6% | -167.3% |
| FCF Margin | -156.5% | -13.9% | -142.6% |
| ROE | -316.6% | -40.4% | -276.2% |
| ROA | -136.5% | -32.0% | -104.5% |
| Current Ratio | 1.59 | 2.84 | -1.25 |
| Debt / Equity | — | 0.28 | — |